Photo by helloimnik from unsplash
Data from the United States, Surveillance, Epidemiology, and End Results Program reveal that hepatocellular carcinoma (HCC) 5- year relative survival is 20.3% livibd.html). ‘Approximately, 1.0% of men and women will… Click to show full abstract
Data from the United States, Surveillance, Epidemiology, and End Results Program reveal that hepatocellular carcinoma (HCC) 5- year relative survival is 20.3% livibd.html). ‘Approximately, 1.0% of men and women will be diagnosed with liver and intrahepatic bile duct cancer at some point during their lifetime, based on 2016–2018 data’. And yet, in the 45% confined to the liver, the 5- year relative survival is 35.3%. Notably, 50%–60% of patients with HCC will receive systemic therapies, 1 including immune check- point inhibitors (ICIs). The overall response rate to ICIs ranges from 7% to 36%, thus understanding who may ( cui therapy. a work Montironi molecular study dissect the immunogenomic patterns to predict ICIs response. thorough HCC
Journal Title: Gut
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!